KPV

KPV is three amino acids long - lysine, proline, valine - and that is the whole molecule. It is the tail end of alpha-melanocyte-stimulating hormone, and it turns out to be the part of that hormone that calms inflammation. Cut α-MSH down to its last three residues and you lose the pigmentation signalling but keep the anti-inflammatory signalling. That separation is why KPV has been studied since the 1990s and why an FDA advisory committee voted to recommend it for pharmacy compounding in July 2026.

What it does not have is a single human clinical trial. The evidence base is mouse colitis models, cell work, and delivery-vehicle engineering. Below is what those studies found, what the FDA vote actually did, and what 33 independently tested vials say about the material being sold.

What is KPV and where does it come from?

Alpha-MSH is a thirteen-residue hormone best known for driving pigmentation. It is also a potent anti-inflammatory. In the 1990s researchers worked out that those two jobs live in different parts of the molecule, and that the anti-inflammatory job survives being cut down to residues 11 through 13: Lys-Pro-Val.

The interesting consequence is the delivery route. Full α-MSH signals through melanocortin receptors. KPV mostly does not. Instead it is carried into intestinal epithelial and immune cells by PepT1, a di- and tripeptide transporter that the gut normally uses to absorb protein fragments. PepT1 is upregulated in inflamed intestinal tissue, which means the transporter delivering KPV is more active exactly where the inflammation is.

Once inside the cell, KPV suppresses NF-κB and MAP-kinase signalling and cuts pro-inflammatory cytokine output. Because uptake is transporter-mediated rather than receptor-mediated, it is active at nanomolar concentrations in cell work.

For contrast, melanotan II is the other well-known molecule derived from this same hormone, and it goes the opposite direction - built to hit melanocortin receptors hard for the pigmentation effect KPV deliberately leaves behind.

What does the KPV research actually show?

Two 2008 papers are the foundation, and both are mouse work.

Dalmasso and colleagues, publishing in Gastroenterology, showed PepT1-mediated uptake of KPV reducing intestinal inflammation, establishing the transporter mechanism. In the same year Kannengiesser and colleagues reported in Inflammatory Bowel Diseases that KPV had anti-inflammatory potential across murine IBD models. Later work concentrated on the delivery problem, since a free tripeptide clears quickly, and moved toward nanoparticle and hydrogel carriers designed to hold KPV at the intestinal wall.

The honest summary of the evidence is:

That last row is the one to hold onto. KPV has a plausible mechanism and consistent animal data. It has never been tested in a controlled human trial for any indication.

Did the July 2026 FDA vote make KPV legal?

No, and the gap between what happened and how it is being described is wide.

On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend KPV for the 503A Bulks List, nominated for wound healing and inflammatory conditions. KPV had already been removed from the Category 2 do-not-compound list in April 2026, alongside eleven other substances.

Neither step makes compounding lawful. Category 2 removal does not confer eligibility, and an advisory recommendation is not a rule. FDA must either complete notice-and-comment rulemaking, which analysts expect to run into 2027 or beyond, or separately grant interim Category 1 status. FDA's own review scientists recommended against all seven peptides on the agenda, citing insufficient safety and efficacy data.

The full breakdown of what the vote changed and what it did not is in our FDA peptide vote explainer. The short version for KPV specifically: nothing about its legal status changed in July, and nothing about it changed for the research-chemical market at all.

How pure is the KPV being sold?

This is where we can add something the rest of the internet cannot. We mirror third-party certificates of analysis rather than repeating vendor claims, and KPV turns out to be one of the cleanest compounds in the corpus.

Across 33 KPV certificates issued by Kovera Labs, covering 30 different vendors, certified between 16 February and 10 June 2026 and retrieved from Kovera's verifier on 2 August 2026:

The content result is the more unusual finding. Thirty-two of the 33 vials were labelled 10 mg and measured between 10.69 mg and 12.88 mg. The single 5 mg vial measured 5.31 mg. Every one was overfilled rather than underfilled, which is the opposite of the pattern that shows up on higher-value compounds where shorting the vial is worth money. A 10 mg KPV vial is cheap enough that overfilling costs the manufacturer very little.

Two caveats before anyone reads this as a clean bill of health. A certificate covers the batch that was tested, not the vial in your hand, so the lot number on the vial has to match the lot on the certificate. And Kovera revises certificates in place under the same reference number, so a certificate screenshotted months ago may no longer match what the lab serves today. Record the date you retrieved it. You can check any certificate against the issuing lab's own record with our COA verifier, and our read on the lab itself is in is Kovera Labs legit.

What about KPV in the KLOW blend?

KPV is the K in KLOW, a four-peptide blend of GHK-Cu, BPC-157, TB-500 and KPV sold pre-mixed. It shows up in our lab data more often inside that blend than it does alone, in combinations including GHK-Cu with KPV, BPC-157 with TB-500 and KPV, and a Cartalax variant.

A blend collapses four separate identity checks into one, and a single purity figure on a four-component vial tells you far less than four figures on four vials. We have seen exactly that failure in the Kovera data, where pre-mixed blends came back at above 99.8% purity while still failing dose and identity confirmation. High purity does not mean correct identity. The detail is in our KLOW stack research read.

If you are evaluating KPV specifically, single-compound vials are far easier to verify than the blend.

What this means

KPV sits in an unusual position for a research peptide. The mechanism is well-characterised rather than hand-waved, the animal data is nearly twenty years old and has been replicated, and the material actually being sold tests cleaner than almost anything else we track. That is a better starting position than most compounds in this market.

What it lacks is the thing that matters most: any human trial. The FDA vote does not substitute for one, and FDA's own reviewers said as much when they recommended against the nomination. Anyone presenting the July vote as validation of KPV's efficacy is describing a procedural step as if it were a clinical result.

Related reading

• FDA peptide vote 2026 - what the PCAC recommendation changed, and the three gates still standing.
• BPC-157 and TB-500 - the other two compounds recommended on the same day, and KPV's blend-mates.
• GHK-Cu - the fourth KLOW component, removed from Category 2 in April but never voted on.
• Semax and MOTS-c - also recommended in July, with their own third-party testing records.
• KLOW stack research read - why pre-mixed blends are harder to verify than single vials.
• What 1,816 Kovera COAs reveal - the full corpus this page's purity figures come from.